Fluorothymidine F-18(Fluorothymidine F-18) - 在研适应症：急性淋巴细胞白血病，脑癌_专利_临床

概要

基本信息

药物类型

小分子化药、诊断用放射药物

别名

+ [1]

靶点-

作用方式

增强剂

作用机制

PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤免疫系统疾病神经系统疾病+ [1]

在研适应症

急性淋巴细胞白血病脑癌

非在研适应症

急性髓性白血病晚期癌症晚期头颈癌+ [27]

原研机构

National Cancer Institute

在研机构

The Children's Hospital Corp.

Advanced Innovative Partners Inc初创企业

非在研机构

National Cancer Institute

National Institutes of Health

The University of Texas Southwestern Medical Center

+ [3]

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C10H13FN2O4

InChIKeyUXCAQJAQSWSNPQ-ZIVQXEJRSA-N

CAS号287114-80-1

关联

52

项与 Fluorothymidine F-18 相关的临床试验

NCT03633955

/ Recruiting临床1期IIT

Multi-institutional Prospective Pilot Study of Radiology Evaluation of Acute Leukemia Infiltration analyZed by Experimental Imaging

This is a prospective pilot study, the primary aim of which is to determine whether the presence of 18F FLT imaging signal uptake abnormalities correlate with clinically validated evidence of hematopoietic malignant disease (e.g. MRD, molecular, flow or histology) after immunotherapy and other treatments.

开始日期2023-01-19

申办/合作机构

University of Oklahoma

[+1]

NCT04309552

/ Active, not recruiting临床1期IIT

A Phase-I Trial for Simultaneous Imaging of Tumor Hypoxia and Proliferation in Patients With Treatment- Naïve High-Grade Glioma

This is a pilot study to assess a new methodology developed for High Grade Glioma (HGG). FMISO PET (Fluoromisonidazole-PET) allows researchers to study whether tumor cells lack oxygen (hypoxia). FLT PET (Fluorodeoxythymidine-PET) allows researchers to study the increase in the number of cells as a result of cell growth and cell division (proliferation). Tumors that have low oxygen levels and/or are dividing fast shall resist to standard cancer treatment. The study will compare FMISO PET and FLT PET imaging techniques with molecular biomarkers of hypoxia, angiogenesis, and cellular proliferation in tissue. proliferation).This information could help researchers develop new treatment techniques to better treat cancer.

开始日期2021-02-01

申办/合作机构

Weill Medical College of Cornell University

NCT04067115

/ Active, not recruiting临床1/2期IIT

SARC037: a Phase I/II Study to Evaluate the Safety of Trabectedin Administered As a 1-Hour Infusion in Ewing Sarcoma Patients in Combination with Low Dose Irinotecan and 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging

This study evaluates the trabectedin and irinotecan in the treatment of Ewings sarcoma, with a EWS-FLI1 mutation. Patients will also receive an infusion of 18F-FLT in combination with a Positron Emission Tomography (PET) scan to help evaluate the effect of treatment.
Phase I was completed on 11/16/2022. Phase II is actively recruiting.

开始日期2021-01-05

申办/合作机构

Sarcoma Alliance for Research through Collaboration

[+3]

100 项与 Fluorothymidine F-18 相关的临床结果

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的转化医学

登录后查看更多信息

100 项与 Fluorothymidine F-18 相关的专利（医药）

登录后查看更多信息

516

项与 Fluorothymidine F-18 相关的文献（医药）

2024-04-15·Clinical Cancer Research

Noninvasive Stratification of Colon Cancer by Multiplex PET Imaging

Article

作者: Soloviev, Dmitry ; Mackintosh, Agata ; Bielik, Robert ; Campbell, Andrew ; Malviya, Gaurav ; Nixon, Colin ; Lewis, David Y ; Johnson, Emma ; Peters, Adam ; Gilroy, Kathryn ; Lannagan, Tamsin R M ; Brown, Gavin ; Sansom, Owen J ; Jackstadt, Rene

AbstractPurpose:The current approach for molecular subtyping of colon cancer relies on gene expression profiling, which is invasive and has limited ability to reveal dynamics and spatial heterogeneity. Molecular imaging techniques, such as PET, present a noninvasive alternative for visualizing biological information from tumors. However, the factors influencing PET imaging phenotype, the suitable PET radiotracers for differentiating tumor subtypes, and the relationship between PET phenotypes and tumor genotype or gene expression–based subtyping remain unknown.Experimental Design:In this study, we conducted 126 PET scans using four different metabolic PET tracers, [18F]fluorodeoxy-D-glucose ([18F]FDG), O-(2-[18F]fluoroethyl)-l-tyrosine ([18F]FET), 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT), and [11C]acetate ([11C]ACE), using a spectrum of five preclinical colon cancer models with varying genetics (BMT, AKPN, AK, AKPT, KPN), at three sites (subcutaneous, orthograft, autochthonous) and at two tumor stages (primary vs. metastatic).Results:The results demonstrate that imaging signatures are influenced by genotype, tumor environment, and stage. PET imaging signatures exhibited significant heterogeneity, with each cancer model displaying distinct radiotracer profiles. Oncogenic Kras and Apc loss showed the most distinctive imaging features, with [18F]FLT and [18F]FET being particularly effective, respectively. The tissue environment notably impacted [18F]FDG uptake, and in a metastatic model, [18F]FET demonstrated higher uptake.Conclusions:By examining factors contributing to PET-imaging phenotype, this study establishes the feasibility of noninvasive molecular stratification using multiplex radiotracer PET. It lays the foundation for further exploration of PET-based subtyping in human cancer, thereby facilitating noninvasive molecular diagnosis.

2024-01-01·European Journal of Nuclear Medicine and Molecular Imaging

Proliferation and apoptosis after whole-body irradiation: longitudinal PET study in a mouse model.

Article

作者: Böning, Guido ; Steiger, Katja ; Ziegler, Sibylle ; von Ungern-Sternberg, Barbara ; Bläske, Alexandra ; Port, Matthias ; Majewski, Matthäus ; Meindl, Maria ; Bartenstein, Peter ; Schüle, Simone ; Palumbo, Giovanna ; Oos, Rosel ; Lauber, Kirsten ; Lindheimer, Felix ; Lindner, Simon ; Brix, Nikko

AbstractPurposeA reliable method for regional in vivo imaging of radiation-induced cellular damage would be of great importance for the detection of therapy-induced injury to healthy tissue and the choice of adequate treatment of radiation emergency patients in both civilian and military events. This study aimed to investigate in a mouse model if positron emission tomography (PET) imaging with proliferation and apoptosis markers is potentially suitable for this purpose.MethodsFour groups, including twenty mice (wild-type C57BL/6) each, were whole-body irradiated with 0 Gy, 0.5 Gy, 1 Gy, and 3 Gy and examined by PET over a six-month period at defined time points. 3'-[18F]fluoro-3'-deoxythymidine ([18F]FLT) and 2-(5-[18F]fluoropentyl)-2-methyl malonic acid ([18F]ML-10) were used to visualise proliferation and apoptosis. Regional standard uptake values were compared with respect to irradiation dose over time. Histologic data and peripheral blood cell values were correlated with the PET results.ResultsThe hematopoietic bone marrow showed a significantly increased [18F]FLT signal at early time points after radiation exposure (day 3 and day 7). This correlated with blood parameters, especially leukocytes, and histological data. A significantly increased [18F]FLT signal also occurred in the gastrointestinal tract and thymus at early time points. An increased [18F]ML-10 signal related to irradiation doses was observed in the bone marrow on day 8, but there was a high variability of standard uptake values and no correlation with histological data.Conclusion[18F]FLT showed potential to visualise the extent, regional distribution and recovery from radiation-induced cellular damage in the bone marrow, gastrointestinal tract and thymus. The potential of [18F]FLT imaging to assess the extent of bone marrow affected by irradiation might be especially useful to predict the subsequent severity of hematopoietic impairment and to adapt the therapy of the bone marrow reserve. [18F]ML-10 PET proved to be not sensitive enough for the reliable detection of radiation induced apoptosis.

2023-11-01·International journal of hematology

Hematopoiesis in the spleen after engraftment in unrelated cord blood transplantation evaluated by ¹⁸F-FLT PET imaging.

Article

作者: Hosono, Naoko ; Kiyono, Yasushi ; Yamauchi, Takahiro ; Tsujikawa, Tetsuya ; Okazawa, Hidehiko ; Araie, Hiroaki

Cord blood is an important donor source for allogeneic hematopoietic stem cell transplantation (allo-HSCT), with its unique composition and quality of hematopoietic cells. The proliferation site and potency of infused hematopoietic stem cells in humans may vary between stem cell sources. We investigated this possibility in a prospective, exploratory study to assess hematopoietic dynamics using the radiopharmaceutical 3'-deoxy-3'-¹⁸F-fluorothymidine (¹⁸F-FLT), a thymidine analog used in positron emission tomography imaging, before allo-HSCT and on days 50 and 180 after allo-HSCT. We evaluated 11 patients with hematological malignancies who underwent allo-HSCT [five with peripheral blood stem cell transplantation (PBSCT) and six with unrelated cord blood transplantation (UCBT)]. Before allo-HSCT, ¹⁸F-FLT uptake did not differ between the two groups. At day 50, ¹⁸F-FLT uptake in the spleen was significantly greater in the UCBT group than in the PBSCT group (p = 0.0043), with no difference in whole-body bone marrow. At day 180, the differences in spleen uptake had diminished, and there were no differences between groups in whole-body bone marrow or the spleen, except for the sternum. The persistence of splenic hematopoiesis after engraftment in the UCBT group may reflect the complex systemic homing and proliferation mechanisms of cord blood hematopoietic cells.

100 项与 Fluorothymidine F-18 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	Fluorothymidine F-18	-	DB14930

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
淋巴瘤	临床3期	美国	National Cancer Institute	2008-09-29
脑癌	临床2期	美国	The Children's Hospital Corp.	2010-10-01
乳腺癌	临床2期	-	Merck Sharp & Dohme Corp.	2010-04-08
3型乳腺癌	临床2期	美国	National Cancer Institute	2008-12-01
浸润性乳腺癌	临床2期	美国	National Cancer Institute	2008-12-01
局部晚期乳腺癌	临床2期	美国	National Cancer Institute	2008-12-01
喉肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
口腔肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
口咽肿瘤	临床2期	美国	National Institutes of Health	2008-03-01
头颈部鳞状细胞癌	临床2期	美国	National Institutes of Health	2008-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03276676 (CTgov)	临床1/2期	脑癌	10	[18F]Fluciclovine+[18F]FLT (Group A)	範鏇製選鏇艱淵襯齋遞(獵簾鹽醖鑰鬱積鹽餘鏇) = 觸壓鹽築鬱糧選糧繭鑰鬱繭衊窪積鬱繭廠鹽醖 (顧遞獵膚積艱鹹製顧獵, 觸醖壓襯鑰築夢糧觸獵 ~ 願鹽憲糧選鹹鑰憲築選) 更多	-	2024-12-27
NCT03276676 (CTgov)	临床1/2期	脑癌	10	[18F]Fluciclovine+[18F]FLT (Group B)	範鏇製選鏇艱淵襯齋遞(獵簾鹽醖鑰鬱積鹽餘鏇) = 構夢簾繭鹽鏇夢廠壓範鬱繭衊窪積鬱繭廠鹽醖 (顧遞獵膚積艱鹹製顧獵, 憲膚鹽構夢膚憲壓顧簾 ~ 積願範淵構繭襯蓋獵齋) 更多	-	2024-12-27
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (New Diagnosis of Brain Tumor)	糧顧窪鏇製夢憲築鬱窪(觸網構艱窪齋淵選顧構) = 鏇範簾糧艱艱積襯憲窪網壓夢鏇衊醖鑰範艱顧 (願衊鬱襯膚淵齋獵構蓋, 願鏇構簾膚襯構鑰憲構 ~ 積蓋鑰齋鹹糧製積蓋遞) 更多	-	2024-07-11
NCT01244737 (CTgov)	临床2期	脑癌	50	[18F] FLT (Possible Recurrent Brain Tumor)	糧顧窪鏇製夢憲築鬱窪(觸網構艱窪齋淵選顧構) = 襯壓構艱餘憲網鹹構鑰網壓夢鏇衊醖鑰範艱顧 (願衊鬱襯膚淵齋獵構蓋, 選蓋製製範繭鬱夢顧選 ~ 網簾觸壓鑰糧獵齋範獵) 更多	-	2024-07-11
NCT03318497 (CTgov)	临床2期	胰腺腺癌	6	Computed Tomography+3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT	(製壓齋衊廠糧憲顧鹹鹽) = 選膚積鬱簾鑰窪艱窪鏇鹽鑰艱壓鑰獵夢齋憲製 (積觸憲積網艱製鏇遞廠, 範築醖觸鬱衊網淵膚觸 ~ 窪衊廠夢築淵醖鹽壓憲) 更多	-	2022-11-08
NCT01399658 (AMIGO, CTgov)	临床2期	阴道腺癌 \| 宫颈癌 \| 外阴肿瘤	93	Image-guided brachytherapy+3'-Deoxy-3'-18f-Fluorothymidine	衊齋鬱蓋醖積顧膚窪窪(淵醖選壓夢窪顧壓製鹹) = 窪網窪築艱鏇艱簾願鑰鏇築構艱觸壓膚廠網廠 (選襯鏇蓋鹽築觸淵餘網, 衊鑰淵糧衊廠繭糧壓積 ~ 簾廠獵壓願艱齋鏇鑰顧) 更多	-	2022-03-02
EANM2021	N/A	Ki-67	-	18 F-fluorothymidine (Non-irradiation group)	鹹範衊膚獵齋襯蓋願壓(觸簾醖膚壓築遞醖鏇膚) = 製醖廠選艱壓憲蓋積醖遞廠築夢襯簾獵積網構 (鬱顧鹽壓蓋餘鹹膚積鹹 ) 更多	-	2021-09-24
EANM2021	N/A	Ki-67	-	18 F-fluorothymidine (Irradiation group)	鹹範衊膚獵齋襯蓋願壓(觸簾醖膚壓築遞醖鏇膚) = 鏇餘範壓淵製簾鹽選艱遞廠築夢襯簾獵積網構 (鬱顧鹽壓蓋餘鹹膚積鹹 ) 更多	-	2021-09-24
NCT00979810 (CTgov)	N/A	高级别胶质瘤	11	18F-FLT PET Scan	選鏇構遞壓鹽鏇範製淵(襯鬱淵膚襯蓋廠憲蓋鬱) = 鬱鏇窪範遞選鬱顧憲糧襯糧糧願夢淵顧鹽廠製 (齋憲鑰範簾窪選築選繭, 鑰鏇衊淵糧衊網鬱憲網 ~ 鬱壓構鏇鑰觸觸遞繭艱) 更多	-	2020-12-17
EANM2019	N/A	-	-	18 F-FLT	鹹鏇膚糧艱憲淵鹹窪夢(蓋憲繭鹹製衊範範繭鏇) = few 網鏇遞願齋夢簾艱廠糧 (淵餘顧鏇齋鹽範糧餘願 ) 更多	-	2019-09-18
EANM2019	N/A	-	-	18 F-FLT (N-BOC-FLT)	鹹鏇膚糧艱憲淵鹹窪夢(蓋憲繭鹹製衊範範繭鏇) = few 網鏇遞願齋夢簾艱廠糧 (淵餘顧鏇齋鹽範糧餘願 ) 更多	-	2019-09-18
ISC2019	N/A	缺血性卒中 Ki67	-	F-18-fluorothymidine (Rats subjected to transient middle cerebral artery occlusion (MCAO))	鏇製築顧壓餘獵遞蓋範(範獵齋襯鬱範觸簾製鹽) = cerebral FLT binding activity gradually declined from post MCAO day 7 to day 28 in the infarcted brain 範願蓋獵淵膚願膚齋鹹 (憲範糧獵糧鏇襯艱鹽選 ) 更多	-	2019-02-01
NCT00721799 (CTgov)	临床2期	头颈部鳞状细胞癌 \| 喉肿瘤 \| 口咽肿瘤 \| 口腔肿瘤	33	18F-Fluorothymidine PET scan	夢獵製構鏇網製夢鬱艱(積築遞願鹹憲遞繭顧蓋) = 壓襯憲製襯製網鑰壓願觸窪製膚膚襯憲獵糧衊 (鏇構鹹夢餘鏇鏇醖艱憲, 繭構製壓廠窪願艱鑰鹽 ~ 窪鬱選獵遞衊襯廠遞襯) 更多	-	2017-10-03
SNMMI2016	N/A	孤立性肺结节	-	18F-FLT18F-FDG (18F-FLT PET/CT)	遞壓壓齋築鏇壓夢願鏇(觸襯廠窪膚壓願鹹築願) = 顧醖鏇構獵夢衊齋鹹鏇蓋範顧積製醖構糧鑰糧 (網鏇餘衊觸鑰鏇製廠衊 ) 更多	-	2016-05-24